In the same study, one booster shot increased neutralizing titers 2.7-fold among teenagers between 12 and 17 years old, Novavax said Oct. 12.
The vaccine-maker, which began distributing its COVID-19 vaccine after gaining the FDA and CDC’s authorization in July, said the prototype booster doses were well tolerated and side effects were mainly mild to moderate.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.